Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA accepts first sBLA for an immuno-oncology regimen

June 3, 2015

FDA accepts for review sBLA for Keytruda in advanced NSCLC

June 2, 2015

Amgen and Merck & Co. expand immunotherapy collaboration

June 2, 2015

Lilly and AstraZeneca enter clinical trial collaboration to study MEDI-4736 with ramucirumab

June 2, 2015

University of Montpellier and INSERM jointly patent new HER3 antibodies

May 29, 2015

ADC Therapeutics and LivTech sign antibody license agreement

May 28, 2015

Lipo-MERIT: a novel tetravalent RNA cancer vaccine

May 26, 2015

Nivolumab receives EMA recommendation for squamous NSCLC

May 25, 2015

EMA committee hands down positive opinion for Keytruda in advanced melanoma

May 25, 2015

U.S. scientists report anti-EFNA4 antibody-drug conjugates

May 25, 2015

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...